Physostigmine was administered intravenously to 25 patients, anaesthetised with sodium gamma-hydroxybutyrate (CH B), and their emergence from anaesthesia was studied. Physostigmine (2 mg) brought about rapid, safe, reliable and sustained awakening after a " latent period" varying from 2-10 minutes (mean 6·2 minutes±S.D. 2·2) in 24 patients. In the one patient not awake at 10 minutes, a second dose of physostigmine produced awakening in an additional 8 minutes. No serious side effects were attributable to the Physostigmine. This finding may warrant a reconsideration of the place of CH B in anaesthetic practice.
INTRODUCTION
Sodium gamma-hydroxybutyrate (GHB) was introduced into clinical anaesthesia in 1960 (Laborit et al. ] 960). It is a safe intravenous hypnotic, with minimal cardiovascular and respiratory side effects. Recently it has been shown to be a normal constituent of mammalian brain (Roth and Giarman 1970) and it may be involved in the chemistry of normal sleep mechanisms (Laborit 1973) . Hypersensitivity reactions would therefore be very unlikely, and do not appear to have been recorded. Its metabolism is ultimately to carbon dioxide and water via succinate and the Krebs' cycle (Doherty, Stout and Roth 1975) .
GHB has not achieved widespread popularity, a major disadvantage being its slow and unpredictable recovery (Steel 1968 , Vickers 1968 , Solway and Sadove 1965 962, Lund, Humphries and Virtue 1965) .
In this paper we report a study on the effect of physostigmine on the speed of recovery after the administration of GHB in man. METHOD Twenty five patients (19 male, 6 female) were studied. Their ages ranged from 23-76 years (mean 55·5 years). Two patients were ASA category 3, and the remainder were category 1 or 2. All were having surgery under regional blockade (12 caudals, 8 spinals, 4 lumbar epidurals and one axillary block). Premedication was with oral diazepam, 10 mg approximately one hour before induction.
At induction, GHB (50 mgjKg) was administered intravenously. The onset of sleep with GHB is slow (Vickers 1969). It was therefore usually followed by a " sleep dose" of thiopentone (19 patients-mean dose 220 mg) 
or Althesin (4 patients-mean dose 1·6 ml). The local block was established prior to induction in 7 patients and after induction in the other eighteen.
After 60 minutes, if the surgery were not expected to finish within the next 20 minutes, an increment of GHB (10 mgjKg) was given, followed by a similar increment after an additional 30 minutes if the surgery was continuing.
Anaesthesia and Intensive Care, Vol. IV, No. 4, November, 1976 F ~\t the conclusion of surgery, the lcvel of consciousness was assessed on a .:i-point scale as sho\\'n in Table J. Physostigmine ~ mg was then administered intravenously, preceded by atropine () .(j mg if the pulse rate were less than HO beats/minute, The level of consciousness was reassessed eyery ~ minutes. If the patient had not reached either level I or level 11 within 10 minutes, onc furthcr injection of physostigmine ~ mg was gi\'cn. c\.ny significant peripheral cholinergic effects such as bradycardia or salivation were treated with atropine O'H mg.
RbtTI'S GH!) prm'ided a very acceptable form of "sleep coyer" for patients having surgery under regional blockade, There were no untoward sequelae during the surgery, .\lthough all patients \\'ere in a deep sleejl state during the operations, fe\\' required ja\\' support t() maintain an aclc(luate airway, :'Ijost had an oropharyngeal airway inserted and this airway \\'as tolerated without coughing or bucking. Supplementary oxygen \\'as gin'n via a Hudson ox\'gcn mask to most patients. The respiratory minute volume \\'as well maintained, and there \\'ere no cardiovascular changes attributablc to the eHB other tllan the occasional characteristic slight slowing ( A.S."\.
.\ge
Status
: l4 Technique .l1ean : 45·4±17·33 6·2±2·2 -* "'here two or more times are gi,'en these are cases where supplementary doses of GRB were given. All times are measured from the dose of GHB until the administration of physostigmine. Thus U2/32 indicates that the physostigmine was gi,'en 92 minutes after the first (50 mg/Kg) dose of GHB and 32 minutes after the second (10 mg/Kg) dose administration of G HB to the administration of physostigmine varied from 12 minutes to 75 minutes (mean 4.5 minutes±S.D. 17). These times were taken from the administration of the last dose of GHB in those patients who received more than one dose. \Vhen consciousness was assessed at the cnd of surgery, all patients were in level IV or level V. All patients awoke following injection of physostigmine (one patient requiring a second dose), all but one reaching level 1.
Awakening was not a slow continuous progression through the various levels, but tended to be rather abrupt, after a varying "latent period", following injection of the physostigmine. The duration of this latent period is shown in Table 2 , and varied from 2 minutes to 10 minutes (mean 6·2 minutes ±S.D. 2· 2) except in the only case where a second dose of physostigmine was required. The first dose had no apparent effect on this patient. Following the second dose he awoke to level I after a " latent period" of 8 minutes. The actual awakening occasionally caused the patients to appear momentarily startled, but they did not find the experience unpleasant in retrospect. Some patients, though awake, appeared sedated, but were orientated and able to converse. Others were fully alert. A few subsequently lapsed into a light sleep, but awoke readily when called by name or shaken by the shoulder. None required a repeat dose of physostigmine once awake.
Atropine was administered prior to the physostigmine in four cases, and did not appear to influence the arousal time following physostigmine (mean time in these cases was 5 minutes±S.D. 2·1 versus mean of 6·3±S.D. 2·2 for physostigmine without atropine). Atropine was administered following the physostigmine in two cases-once for salivation and once for bradycardia (pulse rate dropped from 60 to 50 beats/minute). In most patients there was no change in pulse rate following the physostigmine, and in none did the rate drop more than 10 beats/minute. Pulse rate and blood pressure usually increased slightly as the patient awoke. No patients developed bronchospasm following the physostigmine nor did any patient urinate, defaecate or complain of abdominal colic.
No patients admitted experiencing dreams or hallucinations during awakening or in the post-operative period. Most patients could subsequently clearly recall events from the initial waking onwards.
DrSCl.:SSIO:\f
The prolonged recovery has been the principal drawback to a more widespread acceptance of GHB, despite its obvious advantages. In one series (Steel 1968),160 patients who had been premedicated with pethidine and promethazine, received epidural analgesia and GHB 50 mg/Kg. Their mean sleep time was 2·25 hours. In our previous experience with the drug in anaesthesia for microlaryngoscopy (Unpublished observation), the mean sleep time after admission to the recovery room was 125·4 minutes±S.D. il6 '3, ranging from 37 to 2.50 minutes. In these patients small doses of thiopentone and chlorpromazine were used in addition to GHB 60 mg/Kg and topical analgesia.
This study was purposely conducted on patients having surgery under regional blockade, so that the recovery times would not be influenced by other drugs. It was considered that the small doses of thiopentone or Althesin given to facilitate induction would not be likely to have any significant effect on the conscious state when this was assessed at the end of surgery.
We did not feel justified in arranging this study as a double blind trial. ~he published studies on G HB anaesthesia m man are unanimous that the recovery is long and unpredictable, and this was confirmed by our own previous experience with the drug. Indeed, it was this very feature which led us to abandon GHB as an anaesthetic for microlaryngoscopy. Our preliminary experience with physostigmine was so dramatic that it was not considered ethical to subject some patients unnecessarily to long periods of unconsciousness through the use of a placebo.
These findings may shed some light on the mode of action of GHB. There is evidence that GHB modifies central dopaminergic (Roth and Suhr 1970) and cholinergic (Giarman and Schmidt 1963) pathways. Physostigmine, a tertiary amine, is a centrally-acting anticholinesterase (Goodman and Gilman 1970) , and has been shown to modify the central effects of a wide variety of cholinergic agents, including the belladonna alkaloids (Forrer and Miller 1958) , the benzodiazepines (De Liberti, O'Brien and Turner 1975) , the phenothiazines (Bernards 1973a), and the tricyclic anti-depressants (Slovis et al. 1971) . It is possible that the observed arousal from GHB anaesthesia results from the central anticholinesterase activity of physostigmine. Our findings tend to support the hypothesis R. S. HEXDERSON AND C. l\IcK. HOLl\IES that the anae,;thetic effect of GHB in man results, at least partly, from an action on cholinergic pathways.
Although phy,;ostigmine may have some generalized, non-specific stimulant effect, it has not been shown to produce predictable arousal from any other general anaesthetic agent. A limited study of our department found no significant effect in ketamine, Althesin or barbiturate anaesthesia.
There was a very low incidence of undersirable peripheral choline~gic effects following injection of the physo,;tigllline.
The comparative potencies of different anticholinesterases vary at different sites (Gray 1970) , and detailed information on the potency of physostigmine does not seem to be a\·ailahle. However, our observations are consistent with the reported clinical studies in the systemic use of physostigmine. Bernards (UI73b) described a series of 5,000 cases given phy:-;ostigmine (1 mg 1.\'. or:2 mg 1.:\1.) to treat suspected belladonna toxicity. Ko problems were encountered in any patient from peripheral cholinergic effects. Neither hronchospasm nor bradycardia "'ere observed, most patients again showing instead a small increase in pulse rate. Atropine was not usually administered with the phy,;ostigmine and many of these patients kld recein'd on1\' a small dose of a belladonna as a premedicant' ,;('veral hours previously.
Undoubtedly a safe, reliable antidote would increase the acceptability of G HB, and make it possible to take advantage of the good features of this agent, not only as "sleep cover" for those patients having surgery under local or regional analgesia, but in conventional general anaesthetic techniques as ,,·ell. A further potential application of G H B may be in the development of totally intravenous techniques, thus eliminating inhalational agents with the a,;sociatecl problems of operating theatre pollution.
\\"e conclude that physostigmine reliahly and safely produces a prompt and sustained awakening after the administration of GHB.
